Clinical teams providing biological therapies for people with inflammatory bowel disease (IBD) are maintaining good practices of care despite increased pressures from COVID-19, according to the latest report from the IBD Registry.
The second annual report on the use of biological therapy in the treatment of IBD has been published today, revealing new figures from the IBD Biological Therapies Audit, which monitors in the provision of biological therapies against clinical guidelines for patient safety and quality of care.
Biological therapies can transform patient outcomes, but their use needs to be closely monitored as new biological treatments continue to be developed. NHS Trusts providing care for adults and children with IBD can submit clinical data to the rolling IBD Biological Therapies Audit to help guide the provision of safe and effective therapies.
The number of clinical teams submitting data continues to grow, with more than 8,500 patient records contributing to this report. The Registry’s Medical Director Professor Stuart Bloom said: “The past year with COVID-19 has been a challenging one, and so the continued participation and focus from IBD teams across the country on tracking their biologics care pathways and outcomes for patients deserves both high recognition and thanks.”
The full IBD Biological Therapies Audit Annual Report 2021 is available on the IBD Registry’s KPIs webpage